Updated: Akero redeems its failure in severe MASH with longer-term data
Akero Therapeutics claimed a win in severe MASH on Monday morning, as the company’s candidate efruxifermin showed a 24% benefit on fibrosis reduction over placebo in a crucial mid-stage trial. ...
View ArticleMaze looks to lead IPO queue with $113M Nasdaq debut
Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million Series D. The clinical-stage biotech — which has been through an FTC snafu ...
View ArticleLeerink Partners hires M&A bankers, grows health deals team
In a dramatic turnaround from bankruptcy court less than two years ago, Leerink Partners is now on the offensive and hiring away from rival banks to build out its M&A practice. The healthcare...
View ArticleMetsera outlines $250M IPO plans as obesity biotech competition rises
Metsera, a well-funded biotech trying to angle toward the front of the obesity medicine pack, has proposed a $250 million IPO. That would be the size of net proceeds Metsera would gain from its Nasdaq ...
View ArticleAurion Biotech files for IPO amid legal battle with Alcon
Investors typically celebrate IPOs as milestone moments — and potential exit opportunities — for their startups. In an unusual twist, the eye giant Alcon has taken a different view, suing a startup it...
View ArticleAllakos restructures after Phase 1 failure; AB2 inks deal with Nippon Shinyaku
Plus, news about GSK: Allakos reports Phase 1 failure, lays off 75% of staff: The biotech said AK006 did not produce a clinical benefit in patients with chronic spontaneous urticaria, a ...
View ArticleVeru's drug lessens loss of lean mass in patients taking Wegovy
Veru says its muscle-maintaining drug preserved more lean mass in older patients taking a GLP-1, but skittish investors didn’t celebrate. The Miami biotech on Monday reported new Phase 2b data for ...
View ArticleTrump healthcare transition: Live updates, biotech, pharma news
It’s been one week since President Donald Trump returned to the Oval Office. We've already seen a flood of executive orders, and the pause on health agency communications has created a bit of a frenzy ...
View Article#ASCOGI25: Bristol Myers shares IO combo data in colorectal cancer; Pfizer...
Several drugmakers shared new clinical data at this year’s ASCO GI Symposium in San Francisco, and Endpoints News has rounded up a handful of notable presentations from Bristol Myers Squibb, Pfizer,...
View ArticleSage rejects Biogen’s deal offer, will look at other options
Sage Therapeutics knows it needs to do something. But it doesn't want to sell to its partner Biogen. On Monday, the troubled biotech said its board had unanimously rejected Biogen's ...
View ArticlePfizer inks $60M settlement to close Nurtec anti-kickback suit
Pfizer will pay nearly $60 million to settle claims that its subsidiary Biohaven used illegal kickbacks to drive sales of its migraine medicine Nurtec ODT. A Pfizer spokesperson said the company has...
View ArticleObesity startup Found drives weight loss with low-cost generic drugs over...
Found, a telehealth startup that treats obesity with medication and lifestyle coaching, unveiled new research showing tens of thousands of its patients lost significant amounts of weight through its...
View ArticlePharmacy middlemen lose bid to toss new Hawaii complaint
The state of Hawaii can proceed with a lawsuit against the three largest pharmacy benefit managers after it updated its complaint, a federal judge has ruled. Judge Leslie Kobayashi of the US District...
View ArticleSarepta shares two-year DMD data that may inform Europe decision
Sarepta Therapeutics unveiled new results from the second part of a clinical trial for its Duchenne muscular dystrophy gene therapy Elevidys, showing that patients who received the gene therapy...
View ArticleUpdated: Cell therapy biotech Affini-T Therapeutics reduces staff
Affini-T Therapeutics laid off an undisclosed number of employees last week, CEO Jak Knowles confirmed in a post-publication email to Endpoints News on Tuesday. The startup was coming up on a likely...
View ArticleVersant's fourth obesity biotech starts with $65M and a GIP antagonist
Another obesity biotech emerged on Tuesday morning, this time taking a different approach to the GIP antagonism story than Amgen and another startup called Antag Therapeutics. Helicore Biopharma broke...
View ArticleITM aims to compete with Novartis after Phase 3 radiopharma win
ITM Isotope Technologies Munich plans to seek approval for its β-emitting radioligand in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) following a Phase 3 success, the biotech said Tuesday....
View ArticleAtalanta gets $97M boost to take two siRNAs into clinic for rare neuro disorders
For five years, Atalanta Therapeutics operated with one investor. Now, F-Prime Capital is getting a bevy of financial support to propel two of the Boston biotech's RNAi drugs for rare neurological...
View ArticleLantheus to buy radiopharma player Evergreen Theragnostics for $250M upfront
In its latest move to expand its portfolio, Lantheus Holdings is spending $250 million upfront to buy radiopharma CDMO and diagnostics company Evergreen Theragnostics, which could also receive up to...
View ArticleAkero, 89bio disclose public offerings; BioAge drops Phase 2 obesity drug
Plus, news about Vigonvita Life Sciences and Lutris Pharma: For MASH developers, a race for cash: Akero Therapeutics aims to raise $300 million in an offering that was announced the same ...
View ArticleBiopharma execs split on RFK Jr. before confirmation hearing
Robert F. Kennedy Jr. will sit before a Senate committee on Wednesday and provide the first substantive glimpse into how he may run the nation's health department. Capitol Hill's questioning could...
View ArticleLeap Therapeutics treks toward pivotal study in colorectal cancer, drops...
Leap Therapeutics reported mixed results on Tuesday for an experimental treatment in gastric and colorectal cancer, announcing it is only moving forward with the latter indication. The biotech’s shares...
View ArticleWhat we know — and don’t know — about insurance denial rates
One insurance metric that we don’t often see showing up on earnings calls: the rate at which health plans issue denials. In the wake of UnitedHealthcare CEO Brian Thompson’s murder last month, a lot of...
View ArticleSemaglutide, tirzepatide compounder hit with FDA warning letter
Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and tirzepatide production. The FDA uncovered several issues at ProRx’s facility in...
View Article